openPR Logo
Press release

Biomarkers To Make A Stellar Contribution To The Lysosomal Storage Diseases Market

09-19-2022 06:31 PM CET | Health & Medicine

Press release from: Persistence Market Research

Biomarkers To Make A Stellar Contribution To The Lysosomal

Persistence Market Research delivers key insights on the global lysosomal storage diseases therapeutics market in a new report titled, "Lysosomal Storage Diseases Therapeutics Market: Global Industry Analysis and Forecast, 2016-2026". In terms of revenue, the global lysosomal storage diseases therapeutics market is projected to register a healthy CAGR of 10.0% over the forecast period and is estimated to be valued at US$ 14.36 Bn by 2026. In the report, Persistence Market Research analyzes the key factors and trends impacting the growth and performance of the global lysosomal storage diseases therapeutics market over the forecast period.

Strategizing The Moves For The Next Decade? See Through Sample Of Lysosomal Storage Diseases Market Report! https://www.persistencemarketresearch.com/samples/3145

Company Profiles 

Shire PLC
Pfizer, Inc.
Sanofi
BioMarin Pharmaceutical Inc.
Actelion Ltd.
Raptor Pharmaceutical Corp.
Protalix Biotherapeutics Inc.
Amicus Therapeutics, Inc.
Starting With The New Decade On A Diligent Note In The Lysosomal Storage Diseases Market? https://www.persistencemarketresearch.com/methodology/3145

Drivers and trends influencing the market

An increasing diagnosis rate due to increasing awareness and financial incentives for orphan drug development to recover R&D costs is the primary factor fueling the growth of the global lysosomal storage diseases therapeutics market. Also, an increasing focus of major biopharmaceutical companies on the research and development of drugs for the treatment of rare diseases is expected to boost the global lysosomal storage diseases therapeutics market during the forecast period.

Moreover, the number of treatment options currently in the pipeline is further expected to bolster revenue growth of the global lysosomal storage diseases therapeutics market during the forecast period.

However, heterogeneity of the disease leading to underdiagnoses of lysosomal storage diseases, lack of treatment options, and high cost of treatment are factors likely to hamper the growth of the global lysosomal storage diseases therapeutics market over the forecast period.

Advent of therapies targeting neuropathic manifestations by crossing blood brain barrier (BBB) and therapies that overcome immune response and have better tissue selectivity will define the future landscape of the global lysosomal storage diseases therapeutics market.

How About Obtaining Insights About The Region To Enter Concerning The Lysosomal Storage Diseases Market? Press The "Purchase Now" Button To Have Our Lysosomal Storage Diseases Market Report! https://www.persistencemarketresearch.com/checkout/3145

Market forecast

The global lysosomal storage diseases therapeutics market has been segmented on the basis of Indication (Gaucher's Diseases, Fabry Diseases, Pompe's Syndrome, Mucopolysaccharidosis, Others); Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Others); End User (Hospitals, Clinics); and Region (North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA)).

The Gaucher's Diseases indication segment is estimated to account for 29.7% revenue share of the global lysosomal storage diseases therapeutics market by 2016 end. The Enzyme Replacement Therapy segment was valued at US$ 4,833.8 Mn in 2015 and is expected to exhibit the highest CAGR of 10.0% over the forecast period to reach US$ 13.58 Bn by 2026 end.

The Hospitals end user segment is expected to witness 2.8X increase in revenue over the forecast period and is expected to create absolute $ opportunity of US$ 346.2 Mn in 2017 over 2016.

Among regions, Europe is expected to be the dominant regional market in the global lysosomal storage diseases therapeutics market during the forecast period. The Europe market accounted for the highest revenue share of 34.8% and was valued at US$ 1,773.2 Mn in 2015; and is expected to witness a CAGR of 10.2% during the forecast period.

North America is expected to be the second most lucrative market in the global lysosomal storage diseases therapeutics market and is estimated to represent absolute $ opportunity of US$ 159.6 Mn in 2017 over 2016.

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biomarkers To Make A Stellar Contribution To The Lysosomal Storage Diseases Market here

News-ID: 2740330 • Views:

More Releases from Persistence Market Research

Centrifugal Pumps Market Set to Reach US$ 55.7 Billion by 2032, Insights from Persistence Market Research
Centrifugal Pumps Market Set to Reach US$ 55.7 Billion by 2032, Insights from Pe …
The global centrifugal pumps market is poised for significant expansion, with the market projected to grow from US$ 41.2 billion in 2025 to reach US$ 55.7 billion by 2032, reflecting a CAGR of 4.4%. The growth is primarily fueled by increasing demand for efficient water management solutions across agriculture, industrial manufacturing, and municipal services. Centrifugal pumps play a crucial role in ensuring seamless fluid transfer, reducing energy consumption, and maintaining
CAR T-cell Therapy Market to Touch US$24 Billion by 2032, Reports Persistence Market Research
CAR T-cell Therapy Market to Touch US$24 Billion by 2032, Reports Persistence Ma …
The global CAR T-cell therapy market is experiencing transformative growth, projected to expand from an estimated US$5.8 billion in 2025 to US$24 billion by 2032, reflecting a compound annual growth rate (CAGR) of 25% during the forecast period from 2025 to 2032. This growth trajectory is being driven by a confluence of factors, including rising cancer prevalence, especially hematologic malignancies, and continuous advancements in gene-editing technologies and immunotherapy. As these
Hydraulic Fluid Connector Market Technological Innovations, Efficiency Drivers, and Emerging Opportunities Shaping Fluid Power Systems
Hydraulic Fluid Connector Market Technological Innovations, Efficiency Drivers, …
Hydraulic fluid connectors are used only in fluid power and piping systems for efficient operation in industrial fluid networks. A hydraulic fluid connector is deployed in these systems to increase the total machine performance irrespective of applications. Hydraulic fluid connectors are used to enhance uptime in the remote applications such as oil and gas drilling, pipeline installation and mining. Innovations in the offering of tearout-proof technology for hydraulic
Facial Aesthetics Market Poised for 11.8% CAGR Growth through 2032, Says Persistence Market Research
Facial Aesthetics Market Poised for 11.8% CAGR Growth through 2032, Says Persist …
The global facial aesthetics market is on a trajectory of robust growth. Valued at approximately US$17.15 billion in 2025, it is projected to reach US$37.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 11.8% during the forecast period from 2025 to 2032. This expansion is primarily driven by the growing preference for minimally invasive procedures such as botulinum toxins (botox) and dermal fillers, especially as consumers

All 5 Releases


More Releases for Lysosomal

Healthcare Infrastructure Investments Fueling Growth In The Lysosomal Disease Tr …
The Lysosomal Disease Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Lysosomal Disease Treatment Market Size During the Forecast Period? The Lysosomal Disease Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025
Lysosomal Enzyme Market Size, Share, Trends, Demand & Forecast 2034
The Lysosomal Enzyme Market Is Set To Grow At An Estimated CAGR Of 4.4% From 2025 To 2034, Rising From $8.2 Billion In 2024 To $12.5 Billion By 2034. On April 16, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Lysosomal Enzyme market goods. The market study excludes key regions that are accelerating marketization. This section
The Lysosomal Acid Lipase Deficiency (LAL-D) Market: An Overview
Introduction Lysosomal Acid Lipase Deficiency (LAL-D) is a rare genetic disorder characterized by the body's inability to break down certain fats, leading to the accumulation of lipids in various organs. This condition can cause serious health issues, including liver disease, cardiovascular problems, and metabolic disturbances. With growing awareness and advancements in treatment options, the LAL-D market has garnered increasing attention. This post explores the LAL-D market, focusing on its size, share,
Lysosomal Disease Treatment Market Analysis & Forecast by 2026
According to a new report published by Allied Market Research, titled, "Lysosomal Disease Treatment Market: Global Opportunity Analysis and Industry Forecast, 2019-2026" The lysosomal disease treatment market is expected to witness significant growth during the forecast period due to factors such as allocation of orphan drug status to drugs used for treatment of lysosomal disorder. Moreover, rise in awareness related to early diagnosis of lysosomal diseases is another major factor
Lysosomal Acid Lipase Deficiency Treatment Market Report
As per the research conducted by GME, the Global Lysosomal Acid Lipase Deficiency Treatment market will grow with a CAGR value of 10 percent by 2026. Innovative research and advancements for developing reliable and cost-effective therapies, as well as the introduction of novel drugs, is expected to drive substantial expansion in the lysosomal acid lipase deficiency treatment market. Moreover, the increasing incidence of chronic diseases, as well as other uncommon
Lysosomal Alpha Glucosidase Global Market Research Report 2025
Lysosomal Alpha Glucosidase Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/lysosomal-alpha-glucosidase-market/81018 The report firstly introduced the Lysosomal Alpha Glucosidase basics: definitions, classifications, applications